

IN PURSUIT OF THE IMDC: TURKISH ONCOLOGY GROUP KIDNEY CANCER CONSORTIUM DATABASE (TKCC)

Emre Yekedüz MD¹, Serdar Karakaya MD², İsmail Ertürk MD³, Deniz Tural MD⁴, Cihan Erol MD⁵, Çağatay Arslan MD⁶, Satı Coşkun Yazgan MD⁷, Gökhan Uçar MD⁸, Nihan Şentürk Öztaş MD⁹, Rukiye Arıkan MD¹⁰, Orçun Can MD¹¹, Özlem Nuray Sever MD¹², Saadettin Kılıçkap MD¹³, Sema Sezgin Göksu MD¹⁴, Umut Demirci MD¹⁵, Nuri Karadurmuş MD³, M.Ali Şendur MD⁵, İrfan Çiçin MD¹⁶, Yüksel Ürün MD⁷

¹Ankara Etilik City Hospital, Medical Oncology Clinic, Ankara, TÜRKİYE. ²University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Medical Oncology Department, Ankara, TÜRKİYE. ³University of Health Sciences Gülhane Education and Research Hospital, Medical Oncology, Ankara, TÜRKİYE. ⁴Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, TÜRKİYE. ⁵Ankara Yıldırım Beyazıt University Faculty of Medicine, Medical Oncology Department, Ankara, TÜRKİYE. ⁶Izmir University of Economics, Faculty of Medicine, Department of Medical Oncology, Izmir, TÜRKİYE. ⁷Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE. ⁸University of Health Sciences, Ankara City Hospital, Department of Medical Oncology, Ankara, TÜRKİYE. ⁹Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Division of Medical Oncology, Istanbul, TÜRKİYE. ¹⁰Marmara University, Faculty of Medicine, Department of Medical Oncology, Istanbul, TÜRKİYE. ¹¹University of Health Sciences, Prof. Dr. Cemil Taşçıoğlu City Hospital, Department of Medical Oncology, Istanbul, TÜRKİYE. ¹²Gaziantep University Faculty of Medicine, Medical Oncology Department, Gaziantep, TÜRKİYE. ¹³Istinye University, Faculty of Medicine, Department of Medical Oncology, Istanbul, TÜRKİYE. ¹⁴Akdeniz University Faculty of Medicine, Department of Medical Oncology, Antalya, TÜRKİYE. ¹⁵Üsküdar University, Faculty of Medicine, Memorial Ankara Hospital, Department of Medical Oncology, Ankara, TÜRKİYE. ¹⁶Trakya University, Faculty of Medicine, Department of Medical Oncology, Edirne, TÜRKİYE

Introduction:


- Clinical trials are the main part of evidence-based medicine.
- Some concerns due to the selected patient groups in clinical trials have revealed the necessity of evaluating real-world data (RWD).
- Especially in oncology, the importance of RWD is increasing over time.
- The International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium (IMDC) is one of the excellent examples of the source for the RWD.

Methods:

- Turkish Oncology Group Kidney Cancer Consortium (TKCC) includes patients from 14 high-volume centers in Türkiye.
- The number of patients is increasing with the inclusion of new centers. It is expected to include up to 1,500 patients from 20 centers by 2024.
- Patients' data is constantly updated.

Results:

	Patients	
	n=1001	(%)
Age - years, median (IQR)	60 (54-67)	
Gender		
Male	740	(73.9)
Female	261	(26.1)
Histological Type		
Clear Cell	747	(74.6)
Non-Clear Cell	254	(24.7)
Previous Nephrectomy		
Yes	754	(75.3)
No	232	(23.2)
IMDC Risk		
Favorable	91	(9.1)
Intermediate	357	(35.7)
Poor	192	(19.2)
Treatment Line for Metastatic Disease		
1 st	907	(90.6)
2 nd	565	(56.4)
3 rd	238	(23.8)
4 th	79	(7.9)
5 th	25	(2.5)



Conclusion:

- IMDC is the role model for many researchers interested in genitourinary oncology.
- We created our national mRCC database using the way paved by the IMDC.

